pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Testosterone Par
drug
save

Testim

Marketedupdated 3mo ago
by Par Pharmaceutical Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 8
  • drugtestosterone54 co-mentions · 51 sources
  • drugVogelxo54 co-mentions · 51 sources
  • drugBio T54 co-mentions · 51 sources
  • tagRecall45 co-mentions · 44 sources
  • tagApproval12 co-mentions · 6 sources
  • drugtriamcinolone acetonide Rising10 co-mentions · 10 sources
  • drugTRIAMCINOLONE ACETONIDE10 co-mentions · 10 sources
  • drugtriamcinolone acetonide ER10 co-mentions · 10 sources

all catalysts(0)

nothing on the calendar yet

Trials studying Testim

  • phase2Working Out M0 Bipolar Androgen Therapyrecruitingn=69
  • phase2Supraphysiologic Testosterone Priming Induces Darolutamide Extended Responserecruitingn=60
  • phase352 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadismrecruitingn=100
  • phase2Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)active not recruitingn=51
  • phase2Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancerrecruitingn=50
  • phase4Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal Mennot yet recruitingn=144
  • phase2Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPCrecruitingn=26
  • phase2Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancercompletedn=36
more trials →

Patent cliff

source: FDA Orange Book
first barrier falls
Oct 12, 2026
61 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (38)

  • Mar 17, 2034method-of-use (U-1616)US 11090312
  • Mar 17, 2034method-of-use (U-4367)US 11744838
  • Feb 11, 2034formulationUS 8785426
  • Feb 11, 2034formulationUS 8785426
  • Feb 11, 2034formulationUS 9295675
  • Feb 11, 2034formulationUS 9295675
  • Feb 11, 2034formulationUS 9662340
  • Feb 11, 2034formulationUS 9662340
  • Sep 27, 2027method-of-use (U-1390)US 84359441.1y
  • Feb 26, 2027method-of-use (U-1386)US 8419307198d
  • Feb 26, 2027formulationUS 8807861198d
  • Feb 26, 2027method-of-use (U-1390)US 9289586198d
  • Oct 12, 2026formulationUS 846613661d
  • Oct 12, 2026formulationUS 846613661d
  • Oct 12, 2026formulationUS 846613661d
  • Oct 12, 2026method-of-use (U-1103)US 846613761d
  • Oct 12, 2026method-of-use (U-1103)US 846613761d
  • Oct 12, 2026method-of-use (U-1103)US 846613761d
  • Oct 12, 2026method-of-use (U-1103)US 846613861d
  • Oct 12, 2026method-of-use (U-1103)US 846613861d
  • Oct 12, 2026method-of-use (U-1103)US 846613861d
  • Oct 12, 2026formulationUS 848692561d
  • Oct 12, 2026formulationUS 848692561d
  • Oct 12, 2026formulationUS 848692561d
  • Oct 12, 2026formulationUS 872905761d
  • Oct 12, 2026formulationUS 872905761d
  • Oct 12, 2026formulationUS 872905761d
  • Oct 12, 2026method-of-use (U-1103)US 874188161d
  • Oct 12, 2026method-of-use (U-1103)US 874188161d
  • Oct 12, 2026method-of-use (U-1103)US 874188161d
  • Oct 12, 2026formulationUS 875407061d
  • Oct 12, 2026formulationUS 875407061d
  • Oct 12, 2026formulationUS 875407061d
  • Oct 12, 2026formulationUS 875932961d
  • Oct 12, 2026formulationUS 875932961d
  • Oct 12, 2026formulationUS 875932961d
  • Jun 2, 2026method-of-use (U-1390)US 8993520
  • Jun 2, 2026method-of-use (U-1390)US 9180194

News(10)

  • A new, separate outbreak of the diarrhea-causing parasite
    A win for peptide proponents, autism advisory committees clash, and more health news from Morning Rounds
    stat · 18d ago
  • Expect a clash at today’s FDA peptide panel
    The service members who refused the Covid vaccine, the fastest-growing Ebola outbreak in history, and other health news from Morning Rounds
    stat · 19d ago
  • Opinion: New billing codes likely to raise maternity care costs
    “This change is likely to lead to only modest increases in total medical expenses. However, it coincides with many other factors raising health insurance premiums,” writes Jeff Levin-Scherz.
    stat · 20d ago
  • Opinion: Good riddance to bundled ‘global’ maternal care billing
    New maternal billing codes should create a transparent system where both patients and clinicians can thrive, ACOG writes.
    stat · 20d ago
  • Job dissatisfaction and health care access uncertainty grows in the U.S., new study finds
    What Hawaii's wildfires can teach the nation about health recovery, 4.5 million people disenrolled from SNAP, and more health news
    stat · 20d ago
  • Opinion: STAT+: Hospitals’ AI may be drifting. Who’s watching?
    Senior leaders must treat AI governance as their own daily job, not something the technology committee handles quarterly, write Peter Pronovost, Justin Norden, and Kedar Mate.
    stat · 21d ago
  • Opinion: STAT+: I’m a cardiologist. I’m not sure the new cholesterol drug enlicitide is a game-changer
    “In truth, I don’t anticipate prescribing patterns changing immediately,” cardiologist Vishal Khetpal writes of the new cholesterol drug Lipfendra.
    stat · 21d ago
  • Opinion: Pete Hegseth, ‘The Odyssey,’ and the testosterone myth
    The poet didn’t say “sing to me, Muse, of a man with optimized endocrine panels," writes urologist Elizabeth Dray.
    stat · 21d ago
  • A renewed push from the right against abortion pills
    The latest on cyclospora, THC sodas at the grocery store, and more health news from Morning Rounds
    stat · 21d ago
  • Opinion: How a controversial rule could hurt the NIH’s ability to manage risk
    The proposed rule could “weaken the NIH’s benign influence over research risks,” writes Doni Bloomfield.
    stat · 22d ago
view all news mentions →
brand
Testosterone Par
generic
testosterone
indication
Secondary (Hypogonadotropic) Hypogonadism
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 24m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?